You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Schizophrenia, Bipolar Disorders, and Diabetes: Interrelationships and Interventions

  • Authors: Moderator: Richard S. Beaser, MD; Faculty: Philip Levy, MD, John W. Newcomer, MD
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
Start Activity


Target Audience and Goal Statement

This educational activity has been developed for psychiatrists, psychiatric nurses, pharmacists, and other clinicians who treat patients with severe psychiatric conditions.

Upon completion of this activity, participants will be able to:

  1. Recognize the signs and symptoms of the metabolic syndrome in people with schizophrenia and bipolar disorders, whether or not related to its treatments.
  2. Apply knowledge of the pharmacology of antipsychotic medications to more effectively utilize these treatment tools in people with schizophrenia and bipolar disorders.
  3. Describe the interrelationships between conditions and treatments of schizophrenia, bipolar disorders, and the metabolic syndrome.
  4. Select antipsychotic treatments that balance psychiatric treatment impact, macrovascular risk considerations, and the potential for development of the metabolic syndrome.
  5. Initiate preventive and/or therapeutic interventions, or seek consultative assistance to do so, when manifestations of diabetes or other components of the insulin resistance syndrome or metabolic syndrome are present.


Author(s)

  • Richard S. Beaser, MD (Moderator)

    Assistant Clinical Professor of Medicine, Harvard Medical School; Medical Executive Director, Professional Education, Joslin Diabetes Center, Boston, MA

    Disclosures

    Disclosure: Consultant: Aventis Pharmaceuticals, Wyeth Pharmaceuticals; Speaker's Bureau: Aventis Pharmaceuticals, Wyeth Pharmaceuticals.

  • Philip Levy, MD

    Clinical Professor of Medicine, University of Arizona College of Medicine, Tucson, Arizona, Phoenix Endocrinology Clinic Ltd, Phoenix, Arizona

    Disclosures

    Disclosure: Grant/Research Support: Aventis Pharmaceuticals, Merck and Company, Inc., Novo Nordisk Pharmaceuticals Inc., Pfizer Inc., Takeda Pharmaceuticals North America, Inc; Speaker's Bureau: Aventis Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Novo Nordisk Pharmaceuticals Inc., Pfizer Inc., Takeda Pharmaceuticals North America, Inc.; Consultant: Aventis Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Novo Nordisk Pharmaceuticals Inc., Pfizer Inc., Takeda Pharmaceuticals North America, Inc.

  • John W. Newcomer, MD

    Associate Professor of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.

    Disclosures

    Disclosure: Grant/Research Support: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, Pfizer Inc.; Consultant: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceutica, Pfizer Inc.; Speaker's Bureau: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Janssen Pharmaceutica, Pfizer Inc.


Accreditation Statements

    For Physicians

  • The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The Joslin Diabetes Center designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

CME

Schizophrenia, Bipolar Disorders, and Diabetes: Interrelationships and Interventions: Flash Section

processing....

Flash Section

  1. Schizophrenia, Bipolar Disorders and Diabetes: Interrelationships and Interventions
    by Richard S. Beaser, MD; Philip Levy, MD; and John W. Newcomer, MD
    Introduction
    Schizophrenia and Cardiovascular Risk
    Components, Characteristics, and Criteria of the Metabolic Syndrome
    The Increased Metabolic Risk in the Schizophrenic and Bipolar Patient
    Obesity and the Metabolic Syndrome
    Metabolic Adverse Effects of Antipsychotic Agents: Weight Gain
    Metabolic Adverse Effects of Antipsychotic Agents: Insulin Resistance
    Metabolic Adverse Effects of Antipsychotic Agents: Dyslipidemia
    Correlation of A1C Values and Diabetes Complications
    Goals of Diabetes Therapy
    Treatment of Schizophrenia and Bipolar Disorders
    Real and Perceived Risks of Antipsychotic Agents
    Optimizing Therapy With Antipsychotic Agents
    Oral Drug Therapy for Type 2 Diabetes
    Oral Drug Therapy for Type 2 Diabetes: Review of Drug Classes
    Important Considerations for Type 2 Diabetes Treatment in Patients With Schizophrenia and Bipolar Disorders
    Summary and Conclusion